Duelo y Tristeza

Elevated serum amylase is a classical diagnostic biomarker for acute pancreatitis, with levels exceeding three times the upper limit of normal forming part of the revised Atlanta Classification diagnostic criteria. In chronic pancreatitis, amylase output is reduced due to exocrine pancreatic insufficiency, and amylase is a key component of PERT used to restore digestion.

Berberine (BBR), a plant alkaloid from traditional Chinese medicine herbs, has demonstrated anti-inflammatory activity against both acute and chronic pancreatitis in preclinical models. It inhibits JNK, NF-κB, and MAPK signaling, reducing serum amylase, lipase, TNF-α, IL-1β, and IL-6 in cerulein- and L-arginine-induced mouse models. A 2020 study showed berberine attenuates chronic pancreatitis fibrosis via AMPK-mediated inhibition of TGF-β1/Smad signaling.

Beta-carotene has been included in antioxidant combination regimens studied in multiple RCTs for chronic pancreatitis pain relief. A systematic review found that the antioxidant cocktail (selenium, beta-carotene, vitamin C, vitamin E, methionine) significantly reduced pain in chronic pancreatitis patients. A 2024 rat study also demonstrated beta-carotene alone reduced oxidative stress markers and inflammatory gene expression in L-arginine-induced acute pancreatitis.

Chronic pancreatitis leads to exocrine pancreatic insufficiency (EPI), for which pancreatic enzyme preparations (pancreatin), including bovine-derived forms, have been used clinically since the late 1800s. Multiple RCTs and a 2017 meta-analysis (17 studies, 511 patients) confirm that PERT significantly improves fat and nitrogen absorption versus placebo in CP-related EPI. A 1-year prospective multicenter study (294 patients) found gastrointestinal symptoms and recurrent pain were significantly reduced (P<0.001). Bovine preparations are a recognized alternative to porcine, though with lower lipase activity.

Multiple preclinical studies in rat and mouse models show curcumin inhibits NF-κB and AP-1 activation, reducing pancreatic inflammation in both ethanol and non-ethanol pancreatitis models. A small randomized pilot trial in tropical pancreatitis patients demonstrated significant reductions in oxidative stress markers (MDA) and increases in glutathione with 500 mg curcumin plus piperine for 6 weeks. More recent work shows curcumin ameliorates cerulein-induced chronic pancreatitis fibrosis via Nrf2/HO-1 signaling in mouse models.

DHA, a long-chain omega-3 fatty acid, has been shown in a rat cerulein model to inhibit NF-κB and PKCδ activation, reduce IL-6 expression, and limit oxidative damage in the pancreas, suggesting potential to prevent or ameliorate pancreatitis. Omega-3 fatty acid supplementation including DHA has been studied in clinical nutrition trials in acute pancreatitis.

Gardenia jasminoides has been directly tested in a cerulein-induced acute pancreatitis mouse model, demonstrating protective effects including reduced pancreatic weight/body weight ratio, lower serum amylase and lipase, and suppressed pro-inflammatory mediators TNF-α, IL-1β, and IL-6. Geniposide also protects pancreatic beta-cells from oxidative stress damage in diabetes models.

Gardenia jasminoides was shown to protect against cerulein-induced acute pancreatitis in mice (C57BL/6), significantly reducing pancreatic edema, amylase/lipase levels, and lung injury in a dose-dependent manner. Geniposide has also been identified as a promising therapeutic for acute pancreatitis by ameliorating acinar cell injury and oxidative stress. Evidence is preclinical.

L-glutamine is an immunonutrient with antioxidative and gut-barrier-preserving properties that has been evaluated in clinical trials for acute pancreatitis. Glutamine-supplemented total parenteral nutrition reduced blood mononuclear cell IL-8 release in severe acute pancreatitis in a clinical study. Multiple nutrition reviews and trials support intravenous glutamine's benefits in AP patients receiving total parenteral nutrition.

Chronic pancreatitis destroys pancreatic acinar cells, reducing lipase output and causing exocrine pancreatic insufficiency (EPI). Lipase-containing pancreatic enzyme replacement therapy (PERT) is the established treatment. Multiple RCTs and meta-analyses confirm that PERT significantly improves fat absorption and reduces steatorrhea in chronic pancreatitis patients. Recommended dosing is 25,000–40,000 lipase units per meal using enteric-coated microspheres.

In chronic pancreatitis with exocrine insufficiency and steatorrhea, MCTs are a clinically used dietary intervention because their absorption does not require pancreatic lipase or bile salts. A small study in 8 chronic pancreatitis patients found MCT consumption reduced postprandial pain by minimizing CCK stimulation. MCT oil is recommended by clinical gastroenterology guidance when standard pancreatic enzyme replacement is inadequate.

Melatonin, produced endogenously from L-tryptophan, has receptors in pancreatic tissue and has demonstrated protective effects against acute pancreatitis in numerous experimental studies and clinical observations. It reduces ROS/RNS, preserves antioxidant enzyme activity, decreases TNF-α, improves pancreatic blood flow, and reduces apoptosis and necrosis. Clinical reviews indicate potential for prevention of post-ERCP pancreatitis.

Milk thistle's active constituent silymarin has shown anti-inflammatory effects against pancreatitis in preclinical models, attenuating cerulein-induced acute pancreatitis in mice by inhibiting p38 MAPK signaling and reducing oxidative stress, cytokines TNF-α and IL-6, and tissue damage. Small-scale clinical studies have reported symptom improvements in chronic pancreatitis patients. Traditional use includes recommendation for alcohol-related chronic pancreatitis.

NAC has been studied as an antioxidant therapy in both acute and post-ERCP pancreatitis due to its glutathione-precursor and anti-inflammatory properties. Animal studies show it improves pancreatic microvascular perfusion and reduces necrosis in acute necrotizing pancreatitis. A 2007 randomized double-blind placebo-controlled trial (n=43) of IV antioxidants including NAC in severe AP found no significant benefit on organ dysfunction, showing mixed clinical results.

Omega-3 fatty acids have been studied as immunonutritional supplements in acute pancreatitis management through multiple clinical trials. They reduce pro-inflammatory cytokine production and have been shown to attenuate systemic inflammatory sequelae in experimental pancreatitis. Multiple clinical nutrition reviews and trials support their inclusion in enteral/parenteral nutrition formulations for severe acute pancreatitis.

Quercetin, a natural flavonoid, demonstrates antioxidant, anti-inflammatory, and immunomodulatory properties relevant to acute pancreatitis (AP) in multiple preclinical studies. In cerulein-induced AP mouse models, quercetin pretreatment reduced pancreatic edema, inflammatory cell infiltration, acinar necrosis, TNF-α expression, and myeloperoxidase activity. A 2025 comprehensive review in Frontiers in Pharmacology highlights its multifaceted therapeutic potential for AP, though clinical validation is still needed.

Resveratrol, a natural polyphenol, has been reviewed as a potential medical drug for acute pancreatitis due to its anti-inflammatory and antioxidant mechanisms. In animal studies it reduces TNF-α, IL-6, NF-κB activation, serum amylase, and pancreatic microvascular damage. A 2021 comprehensive review concluded it may attenuate AP and its complications through cytokine suppression.

Multiple meta-analyses of RCTs support rhubarb as an adjunct in severe acute pancreatitis (SAP), reducing hospitalization duration, abdominal pain, inflammatory markers, and mortality when added to standard care or early enteral nutrition. A 2020 meta-analysis of 11 RCTs (724 patients) showed significant improvements across all clinical parameters.

Selenium deficiency has been identified in patients with chronic pancreatitis, and selenium-containing antioxidant combinations have been studied in multiple RCTs for chronic pancreatitis pain relief. A double-blind placebo-controlled RCT (n=36) using a combination including organic selenium showed significant pain reduction and quality of life improvement in chronic pancreatitis patients. The clinical evidence for selenium as part of antioxidant cocktails (with vitamins C, E, beta-carotene, methionine) is supported by systematic reviews.

Silymarin has been investigated for pancreatic protection in the context of its anti-inflammatory and antioxidant properties. Its use in pathological conditions of the pancreas is documented in review literature. It is noted as potentially relevant to pancreatitis via oxidative stress reduction and cytokine suppression, but dedicated large-scale human RCTs for pancreatitis specifically are limited.

SPMs have demonstrated efficacy in preclinical chronic pancreatitis models. Pancreatic inflammation involves macrophage and neutrophil infiltration processes that SPMs actively counter. Pancreatitis is listed in validated SPM efficacy compilations based on the Serhan Cold Spring Harbor Perspectives reference.

Stigmasterol protected against acute pancreatitis in a sodium taurocholate (STC)-induced mouse model by targeting the ERK1 signaling pathway, reducing lipase, amylase, acinar cell necrosis, and systemic inflammation. Evidence is preclinical only.

Vitamin C (ascorbic acid) has been studied both as monotherapy and in antioxidant combinations for pancreatitis. Multiple RCTs of combined antioxidants (including ascorbic acid, beta-carotene, vitamin E, selenium, methionine) showed pain reduction in chronic pancreatitis. An open observational study found vitamin C 0.5 g/day plus vitamin E for 12 months abolished pain in 44% of 70 chronic pancreatitis patients. Clinical evidence is mainly as part of combination antioxidant regimens.

Vitamin E (alpha-tocopherol) has been evaluated in combination antioxidant regimens for chronic pancreatitis pain management. Multiple placebo-controlled RCTs of combination antioxidants including vitamin E showed significant pain reduction in chronic pancreatitis. A meta-analysis found statistically significant pain benefit in RCTs using methionine-containing combinations that invariably included vitamin E.